<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505439</url>
  </required_header>
  <id_info>
    <org_study_id>VENUS-MUI</org_study_id>
    <nct_id>NCT01505439</nct_id>
  </id_info>
  <brief_title>A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence</brief_title>
  <official_title>A Prospective, Open Label, Single Arm, Multicenter Study to Estimate the Efficacy and Safety of Solifenacin in Female With Clinically Significant Stress Urinary Incontinence and Urgency Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeong Gu Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the effects of solifenacin on urgency urinary incontinence
      symptoms and incontinence quality-of-life (I-QoL) in female patients with clinically
      significant stress urinary incontinence accompanied by urgency urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in the mean number of urge urinary incontinence episodes per 24 hours</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of urge urinary incontinence episodes per 24 hours</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
    <description>urgency episodes: defined as those with a Bladder Sensation Scale rating of ≥ 3 in the voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean frequency of urination per 24 hours</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in the mean frequency of urination</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of severe urgency episodes per 24 hours</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
    <description>severe urgency episodes: defined as those with a Bladder Sensation Scale rating of ≥ 4 in the voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in overactive bladder symptom score (OABSS) questionnaire</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
    <description>Change in total and each of OABSS items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in short urogenital distress inventory (UDI-6)</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
    <description>Change in total and each UDI-6 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in short incontinence impact questionnaire (IIQ-7)</measure>
    <time_frame>Baseline, week 4 and week 12</time_frame>
    <description>Change in total and each of IIQ-7 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence and severity of side effects</measure>
    <time_frame>For 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <condition>Urgency Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Solifenacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>Solifenacin group</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are selected from those who meets one of criteria

          -  Patients with a positive cough provocation test

          -  Based on 3-day voiding diary, patients with:

               -  Urinary frequency (eight or more micturitions per day or 24 hours)

               -  Urinary urgency (two or more episodes per day or 24 hours)

               -  Urge incontinence (three or more episodes for 3 days)

        Exclusion Criteria:

          -  Breast-feeding women or females of childbearing potential with the intention to become
             pregnant during the study

          -  Post-void residual urine volume (PRV) of 150 cc or more

          -  Patients who experienced acute ureteral obstruction requiring an indwelling catheter

          -  Patients who experienced clinically significant pelvic organ prolapse or lower urinary
             tract surgery within 6 months prior to the initiation of the present study

          -  Patients who underwent a urinary incontinence operation within 1 year

          -  Any condition that, in the opinion of the investigator, is a contraindication for
             anticholinergic treatment, including severe narrow-angled glaucoma, urinary retention,
             gastric retention, severe myasthenia, severe hepatic insufficiency or severe
             ulcerative colitis

          -  Significant hepatic or renal disease, defined as having greater than twice the upper
             limit of the reference ranges for serum concentrations of aspartate aminotransferase
             (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase or
             creatinine

          -  Patients who have any of neurological disorders such as stroke, multiple sclerosis,
             spinal cord injury, and Parkinson's disease

          -  Patients who use an indwelling catheter or practice intermittent self-catheterization

          -  Recurrent UTIs defined as having been treated for symptomatic UTIs 3 times or more in
             the last year

          -  Symptomatic acute urinary tract infection (UTI) during the run-in period

          -  Patients who received any of the following prohibited concomitant drugs within 14 days
             prior to randomization: Treatment performed within the 14 days preceding
             randomization, or expected to initiate treatment during the study with:

               -  Any anticholinergics other than the trial drug

               -  Any drug treatment for overactive bladder. Estrogen treatment started more than 2
                  months prior to inclusion is allowed

          -  Patients taking an unstable dosage of any drug with anticholinergic side effects, or
             expected to start such treatment during the study

          -  Patients with chronic constipation or history of severe constipation

          -  Treatment with any of potent CYP3A4 inhibitors, such as cyclosporine, vinblastine,
             macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin) or antifungal
             agents (e.g. ketoconazole, itraconazole, micronazole)

          -  Sexually active females of childbearing potential not using reliable contraception for
             at least 1 month prior to study initiation and not agreeing to use such methods during
             the entire study period and for at least 1 month thereafter. Reliable contraceptive
             methods are defined as intrauterine devices (IUDs), combination type contraceptive
             pills, hormonal implants, double barrier method, injectable contraceptives, surgical
             procedures (tubal ligation or vasectomy), or continence

          -  Any other condition which, in the opinion of the investigator, makes the patient
             unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site KR00001</name>
      <address>
        <city>Chonam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00002</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00003</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIte KR00004</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00005</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00006</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Gu Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>solifenacin</keyword>
  <keyword>bladder symptom</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

